AceVector (Snapdeal) IPO Allotment Status: Check on MUFG Intime, BSE & NSE

Md Salman Ashrafi Image

Md Salman Ashrafi

Last updated:
3 min read
Acevector (Snapdeal) IPO Allotment Status: KFinTech, BSE, NSE
Table Of Contents
  • Important Dates
  • How to Check Acevector (Snapdeal) IPO Allotment Status?
  • Acevector (Snapdeal) IPO Subscription Details
  • What’s Next After Allotment?
  • Final Word

AceVector IPO allotment is scheduled for September 30, 2026, after the issue closed with 4.93x overall subscription. Retail investors subscribed 4.617x, while NII demand was higher at 8.158x. Investors can check allotment through BSE, NSE, or MUFG Intime once the basis of allotment is finalised.

Important Dates

  • Allotment Date: September 30, 2026
  • Refund Initiation: October 1, 2026
  • Demat Credit: October 1, 2026
  • Listing Date: October 5, 2026

How to Check Acevector (Snapdeal) IPO Allotment Status?

Method 1: Check on BSE

  • Open the BSE IPO allotment status page: https://www.bseindia.com/investors/appli_check.aspx
  • Select AceVector from the issue list.
  • Enter your PAN or application details, as requested.
  • Submit the details.
  • Your allotment status will be displayed once the registrar uploads the information.

Method 2: Check on NSE

Method 3: Check on MUFG Intime (Registrar)

  • Open the MUFG Intime public issues page: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
  • Select AceVector.
  • Choose the identification method available, such as PAN, application number, DP/Client ID or account details.
  • Enter the required information.
  • Submit it to view your application and allotment status.

For future reference, INDmoney's IPO Allotment Status page can also help investors track allotment-related information.

Acevector (Snapdeal) IPO Subscription Details

CategorySubscription
QIB (Qualified Institutional Buyers)3.378x
NII (Non-Institutional Investors)8.158x
RII (Retail Individual Investors)4.617x
Total4.93x

Source: INDmoney

  • The IPO received 4.93x subscription overall, meaning bids were received for nearly five times the shares available in the issue.
  • NII demand was the strongest at 8.158x, followed by retail investors at 4.617x. This means the allotment process becomes particularly important for investors in these oversubscribed categories.
  • The final numbers were materially higher than the subscription levels seen earlier in the issue, showing that demand strengthened as bidding progressed.

Investors who want to understand what these categories mean can refer to INDmoney's IPO Subscription Status guide, which explains QIB, NII and retail participation.

What’s Next After Allotment?

If shares are allotted

Once the basis of allotment is finalised, your status should show the number of shares allotted, if any. The shares are scheduled to be credited to your demat account on October 1.

Because the IPO was oversubscribed, investors may receive fewer shares than they applied for, or no shares at all. After demat credit, the next major event is the October 5 listing on NSE and BSE.

If shares are not allotted

If you do not receive shares, the amount blocked for your application is scheduled to be released from October 1. For UPI applications, this means the UPI mandate should be unblocked rather than money being separately transferred back to you.

The high subscription level means non-allotment is a normal possibility. If you still want exposure to AceVector after allotment, the alternative is to consider the stock after it begins trading on the exchanges.

Final Word

The key point is that 4.93x subscription confirms strong demand, but subscription alone does not determine how AceVector will perform after listing. The company's business fundamentals, valuation and ability to turn growth into sustainable profits remain separate questions.

For now, investors who applied should first check the September 30 allotment result, then verify demat credit or UPI unblocking on October 1.

To prepare for listing day, read our guide on what to do after an IPO lists: sell, hold, or buy.

Read the RA disclaimer here.

Share: